PROTAC degrader inhibitor, Gefitinib-based PROTAC 3, Purity ≥98%

Synonym: 2230821-27-7; GTPL10636; GLXC-25268; EX-A3010; AKOS037653377; AC-36293; BP-28379; (2S,4R)-1-[(2S)-2-[3-[2-[5-[4-(3-Chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypentoxy]ethoxy]propanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide; PROTAC degrader inhibitor

CAS Number: 2230821-27-7
Compound CID: 135156947

Product Size

5 mg; 10 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

Gefitinib-based PROTAC 3, soluble in DMSO and ethanol and insoluble in water, is an effective PROTAC inhibitor, that has the ability to prevent the pathway of PROTAC degrader. The molecular weight of the compound is 934.51, and its molecular formula is C₄₇H₅₇ClFN₇O₈S. It targets the EGFR and EGFR.

Molecular Weight

934.51

Molecular Formula

C₄₇H₅₇ClFN₇O₈S

Targets

EGFR

Form

Lyophilized powder

Purity

≥98%

Impurities

Free from inappropriate visible particulates, foreign matter, discoloration, or other defects.

Solubility

In vitro: DMSO: 92 mg/mL (98.44 mM); Water: insoluble; Ethanol: 92 mg/mL (98.44 mM)

Identity

Confirmed by NMR/HPLC/MS.

Applications

Gefitinib-based PROTAC 3 can be used for its potential to overcome resistance in EGFR-mutant cancers.